StockData
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc. (SPRB) stock

SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$40.49−1.76 (-4.17%)

Close on Nov 17, 2026Market cap $116.37MP/E –Yield –

Spruce Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Spruce Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$47.83M. For fiscal 2025 it was -$36.51M. The highest annual figure on record is -$13.11M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$36.51M–
FY2024Dec 31, 2024-$56.15M–
FY2023Dec 31, 2023-$51.99M–
FY2022Dec 31, 2022-$47.28M–
FY2021Dec 31, 2021-$42.07M–
FY2020Dec 31, 2020-$29.42M–
FY2019Dec 31, 2019-$13.11M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$16.51M–
Q1 FY2026Mar 31, 2026-$11.99M–
Q4 FY2025Dec 31, 2025-$11.10M–
Q3 FY2025Sep 30, 2025-$8.23M–
Q2 FY2025Jun 30, 2025-$2.69M–
Q1 FY2025Mar 31, 2025-$14.49M–
Q4 FY2024Dec 31, 2024-$24.07M–
Q3 FY2024Sep 30, 2024-$9.41M–
Q2 FY2024Jun 30, 2024-$10.04M–
Q1 FY2024Mar 31, 2024-$12.63M–
Q4 FY2023Dec 31, 2023-$11.16M–
Q3 FY2023Sep 30, 2023-$13.66M–
Q2 FY2023Jun 30, 2023-$13.97M–
Q1 FY2023Mar 31, 2023-$13.20M–
Q4 FY2022Dec 31, 2022-$12.11M–
Q3 FY2022Sep 30, 2022-$11.56M–
Q2 FY2022Jun 30, 2022-$11.88M–
Q1 FY2022Mar 31, 2022-$11.73M–
Q4 FY2021Dec 31, 2021-$9.14M–
Q3 FY2021Sep 30, 2021-$11.40M–
Q2 FY2021Jun 30, 2021-$11.71M–
Q1 FY2021Mar 31, 2021-$9.82M–
Q4 FY2020Dec 31, 2020-$8.34M–
Q3 FY2020Sep 30, 2020-$9.56M–
Q2 FY2020Jun 30, 2020-$6.39M–
Q1 FY2020Mar 31, 2020-$5.13M–
Q4 FY2019Dec 31, 2019-$3.13M–
Q3 FY2019Sep 30, 2019-$2.56M–

More Spruce Biosciences figures

See a number that looks wrong?